A Prospective, Phase-II Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax (GIVeRS) in Patients with Richter's Syndrome

被引：0
|
作者：
Tadmor, Tamar [1 ,2 ]
Benjamini, Ohad [3 ]
Goldschmidt, Neta [4 ]
Kreiniz, Natalia [2 ]
Bairey, Osnat [5 ]
Harel, Reut [6 ]
Inbar, Tsofia [7 ]
Wolach, Ofir [8 ,9 ]
Herishanu, Yair [10 ]
机构：
[1] Technion, Ruth & Bruce Rappaport Fac Med, Haifa, Israel
[2] Bnai Zion Med Ctr, Hematol, Haifa, Israel
[3] Sheba Med Ctr Tel HaShomer, Ramat Gan, Israel
[4] Hadassah Med Ctr, Dept Hematol, Jerusalem, Israel
[5] Rabin Med Ctr, Davidoff Canc Ctr, Petah Tiqwa, Israel
[6] Emek Med Ctr, Dept Hematol, Afula, Ein Dor, Israel
[7] Rambam Hlth Care Campus, Dept Hematol & Bone Marrow Transplantat, Haifa, Israel
[8] Rabin Med Ctr, Inst Hematol, Davidoff Canc Ctr, Petah Tiqwa, Israel
[9] Tel Aviv Univ, Fac Med, Tel Aviv, Israel
[10] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185569
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
    D. H. Palmer
    Y. T. Ma
    M. Peck-Radosavljevic
    P. Ross
    J. Graham
    L. Fartoux
    A. Deptala
    M. Studeny
    D. Schnell
    J. Hocke
    A-B. Loembé
    T. Meyer
    British Journal of Cancer, 2018, 118 : 1162 - 1168
  • [42] A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
    Palmer, D. H.
    Ma, Y. T.
    Peck-Radosavljevic, M.
    Ross, P.
    Graham, J.
    Fartoux, L.
    Deptala, A.
    Studeny, M.
    Schnell, D.
    Hocke, J.
    Loembe, A-B.
    Meyer, T.
    BRITISH JOURNAL OF CANCER, 2018, 118 (09) : 1162 - 1168
  • [43] A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barre Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS)
    Yamaguchi, Nobuko
    Misawa, Sonoko
    Sato, Yasunori
    Nagashima, Kengo
    Katayama, Kanako
    Sekiguchi, Yukari
    Iwai, Yuta
    Amino, Hiroshi
    Suichi, Tomoki
    Yokota, Takanori
    Nishida, Yoichiro
    Kohara, Nobuo
    Hirata, Koichi
    Nishiyama, Kazutoshi
    Yabe, Ichiro
    Kaida, Ken-Ichi
    Suzuki, Norihiro
    Nodera, Hiroyuki
    Tsuji, Shoji
    Koike, Haruki
    Kira, Jun-Ichi
    Hanaoka, Hideki
    Kusunoki, Susumu
    Kuwabara, Satoshi
    JMIR RESEARCH PROTOCOLS, 2016, 5 (04):
  • [44] Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)
    Kumar, Anita
    Soumerai, Jacob D.
    Abramson, Jeremy S.
    Batlevi, Connie Lee
    Chadha, Puja
    Dogan, Ahmet
    Falchi, Lorenzo
    Flaherty, Kelsey
    Friedman, Chaya
    Grieve, Clare
    Ho, Caleb
    Johnson, P. Connor
    Joseph, Ashlee
    Khan, Niloufer
    Mi, Joanna
    Martignetti, Rosalba
    Matasar, Matthew J.
    Owens, Colette
    Ruiters, Jade
    Sechio, Sidney
    Seshan, Venkatraman
    Simkins, Elizabeth
    Abdel-Wahab, Omar
    Zelenetz, Andrew D.
    BLOOD, 2021, 138
  • [45] Change in tumor lysis syndrome risk after lead-in treatment in a phase 1b/2 study of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia.
    Rogers, Kerry Anne
    Huang, Ying
    Ruppert, Amy S.
    Civils, Todd
    Das, Subhashish
    Fedor, Christin
    Whitlow, W. Thomas
    Awan, Farrukh T.
    Maddocks, Kami J.
    Woyach, Jennifer Ann
    Jones, Jeffrey Alan
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial
    Hess, Georg
    Huettmann, Andreas
    Witzens-Harig, Mathias
    Dreyling, Martin H.
    Keller, Ulrich
    Marks, Reinhard
    Ernst, Thomas
    Pott, Christiane
    Viardot, Andreas
    Frontzek, Fabian
    Trautmann, Marcel
    Ruckes, Christian
    Deuster, Oliver
    Rosenwald, Andreas
    Theobald, Matthias
    Lenz, Georg
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (03) : 482 - 491
  • [47] Primary Analysis of a Randomized Phase II Study to Evaluate the Efficacy and Safety of Evobrutinib, a BTK Inhibitor, in Patients with Relapsing MS
    Montalban, Xavier
    Arnold, Douglas L.
    Weber, Martin
    Staikov, Ivan
    Piasecka-Strycznska, Karolina
    Willmer, Jonathan
    Martin, Emily
    Dangond, Fernando
    Wolinsky, Jerry S.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 52 - 53
  • [48] Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
    Affronti, Mary Lou
    Jackman, Jennifer Gamboa
    McSherry, Frances
    Herndon, James E., II
    Massey, Elwood C., Jr.
    Lipp, Eric
    Desjardins, Annick
    Friedman, Henry S.
    Vlahovic, Gordana
    Vredenburgh, James
    Peters, Katherine B.
    ONCOLOGIST, 2018, 23 (08): : 889 - +
  • [49] A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obinutuzumab or Placebo in Combination with Mycophenolate Mofetil in Patients with Active Class III or IV Lupus Nephritis
    Furie, Richard
    Aroca, Gustavo
    Alvarez, Analia
    Fragoso-Loyo, Hilda
    Zuta Santillan, Elizabeth
    Rovin, Brad
    Schindler, Thomas
    Hassan, Imran
    Cascino, Matthew
    Garg, Jay P.
    Malvar, Ana
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [50] A Phase II study of the safety and efficacy oflenvatinib in patients with advanced thyroidcancer
    Takahashi, Shunji
    Kiyota, Naomi
    Yamazaki, Tomoko
    Chayahara, Naoko
    Nakano, Kenji
    Inagaki, Lina
    Toda, Kazuhisa
    Enokida, Tomohiro
    Minami, Hironobu
    Imamura, Yoshinori
    Fukuda, Naoki
    Sasaki, Tatsuya
    Suzuki, Takuya
    Ikezawa, Hiroki
    Dutcus, Corina E.
    Tahara, Makoto
    FUTURE ONCOLOGY, 2019, 15 (07) : 717 - 726
12345